Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALR and ALO in Previously Untreated Mantle Cell Lymphoma
NCT03863184Phase 2Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2019
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of acalabrutinib tablet (Variant 1) and lenalidomide in mantle cell lymphoma (MCL) (2 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Peripheral Blood Minimum Residual Disease (MRD)-Negative Complete Response (CR) Rate at 1 year. Started Oct 2019; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)lenalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03863184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03863184.